Natalizumab Subcutaneous Immunogenicity and Safety Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The primary objective of this study is to evaluate the immunogenicity of natalizumab (BG00002) 300 mg subcutaneous (SC) administered to participants with relapsing multiple sclerosis (RMS). The secondary objectives of the study are to evaluate the safety of natalizumab SC injections and to evaluate the efficacy of natalizumab SC injections on relapses and on new magnetic resonance imaging (MRI) lesions.
Epistemonikos ID: 5d0d78c1d1d87541ac7a25196655b594e575a3a4
First added on: May 11, 2024